JPWO2021226591A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021226591A5 JPWO2021226591A5 JP2022567870A JP2022567870A JPWO2021226591A5 JP WO2021226591 A5 JPWO2021226591 A5 JP WO2021226591A5 JP 2022567870 A JP2022567870 A JP 2022567870A JP 2022567870 A JP2022567870 A JP 2022567870A JP WO2021226591 A5 JPWO2021226591 A5 JP WO2021226591A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- acid sequence
- disease
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022309P | 2020-05-08 | 2020-05-08 | |
| US63/022,309 | 2020-05-08 | ||
| PCT/US2021/031605 WO2021226591A1 (en) | 2020-05-08 | 2021-05-10 | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023525753A JP2023525753A (ja) | 2023-06-19 |
| JPWO2021226591A5 true JPWO2021226591A5 (https=) | 2024-05-22 |
| JP2023525753A5 JP2023525753A5 (https=) | 2024-05-22 |
Family
ID=76197640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567870A Pending JP2023525753A (ja) | 2020-05-08 | 2021-05-10 | Ｓｉｒｐアルファ、ｓｉｒｐベータ１およびｓｉｒｐガンマ抗体、ならびにそれらの使用 |
| JP2022567837A Pending JP2023525298A (ja) | 2020-05-08 | 2021-05-10 | Ｓｉｒｐアルファおよびｓｉｒｐベータ１抗体、ならびにそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567837A Pending JP2023525298A (ja) | 2020-05-08 | 2021-05-10 | Ｓｉｒｐアルファおよびｓｉｒｐベータ１抗体、ならびにそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US12503508B2 (https=) |
| EP (2) | EP4146698A1 (https=) |
| JP (2) | JP2023525753A (https=) |
| KR (2) | KR20230017219A (https=) |
| CN (2) | CN115768795A (https=) |
| AU (2) | AU2021267943A1 (https=) |
| CA (2) | CA3177961A1 (https=) |
| GB (2) | GB2613259A (https=) |
| IL (2) | IL298024A (https=) |
| TW (2) | TW202208431A (https=) |
| WO (2) | WO2021226591A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021226591A1 (en) | 2020-05-08 | 2021-11-11 | Electra Therapeutics, Inc. | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof |
| CN118591619A (zh) * | 2021-11-24 | 2024-09-03 | 雷格细胞股份有限公司 | 人诱导性调节性t细胞及其制作方法 |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
| CN117025547B (zh) * | 2023-10-08 | 2023-12-12 | 迈杰转化医学研究(苏州)有限公司 | 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用 |
| TW202529810A (zh) | 2023-10-19 | 2025-08-01 | 美商電子療法股份有限公司 | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 |
| TW202523701A (zh) | 2023-10-19 | 2025-06-16 | 美商電子療法股份有限公司 | 用於治療癌症之ｓｉｒｐ抗體 |
| WO2025226691A1 (en) | 2024-04-22 | 2025-10-30 | Electra Therapeutics, Inc. | Sirp alpha and beta antibodies for treatment of epstein–barr virus infections |
| CN119192379B (zh) * | 2024-11-22 | 2025-01-28 | 四川省医学科学院·四川省人民医院 | 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| KR20260030924A (ko) * | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| CN118027200A (zh) | 2016-12-09 | 2024-05-14 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| MA47111A (fr) | 2016-12-22 | 2019-10-30 | Univ Wake Forest Health Sciences | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer |
| JP7179743B2 (ja) * | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| CN118271443A (zh) * | 2017-05-16 | 2024-07-02 | 拜奥迪斯私人有限公司 | 抗SIRPα抗体 |
| JP7395471B2 (ja) * | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
| EP3802602A1 (en) * | 2018-05-25 | 2021-04-14 | Alector LLC | Anti-sirpa antibodies and methods of use thereof |
| CA3140904A1 (en) | 2019-06-24 | 2020-12-30 | Amgen Inc. | Inhibition of sirp-gamma for cancer treatment |
| US20230340112A1 (en) | 2020-02-28 | 2023-10-26 | Apexigen, Inc. | Anti-sirpa antibodies and methods of use |
| WO2021226591A1 (en) * | 2020-05-08 | 2021-11-11 | Electra Therapeutics, Inc. | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof |
| WO2023086906A2 (en) | 2021-11-10 | 2023-05-19 | Electra Therapeutics, Inc. | Sirp gamma antibodies and uses thereof |
| TW202523701A (zh) | 2023-10-19 | 2025-06-16 | 美商電子療法股份有限公司 | 用於治療癌症之ｓｉｒｐ抗體 |
| TW202529810A (zh) | 2023-10-19 | 2025-08-01 | 美商電子療法股份有限公司 | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 |
-
2021
- 2021-05-10 WO PCT/US2021/031605 patent/WO2021226591A1/en not_active Ceased
- 2021-05-10 EP EP21729164.0A patent/EP4146698A1/en active Pending
- 2021-05-10 IL IL298024A patent/IL298024A/en unknown
- 2021-05-10 EP EP21730008.6A patent/EP4146699A1/en active Pending
- 2021-05-10 CN CN202180033618.6A patent/CN115768795A/zh active Pending
- 2021-05-10 GB GB2218419.6A patent/GB2613259A/en not_active Withdrawn
- 2021-05-10 AU AU2021267943A patent/AU2021267943A1/en active Pending
- 2021-05-10 CN CN202180033623.7A patent/CN115768796A/zh active Pending
- 2021-05-10 JP JP2022567870A patent/JP2023525753A/ja active Pending
- 2021-05-10 KR KR1020227042951A patent/KR20230017219A/ko active Pending
- 2021-05-10 IL IL297982A patent/IL297982A/en unknown
- 2021-05-10 TW TW110116828A patent/TW202208431A/zh unknown
- 2021-05-10 US US17/923,778 patent/US12503508B2/en active Active
- 2021-05-10 CA CA3177961A patent/CA3177961A1/en active Pending
- 2021-05-10 WO PCT/US2021/031541 patent/WO2021226576A1/en not_active Ceased
- 2021-05-10 CA CA3178038A patent/CA3178038A1/en active Pending
- 2021-05-10 TW TW110116827A patent/TW202208430A/zh unknown
- 2021-05-10 GB GB2218421.2A patent/GB2613464A/en not_active Withdrawn
- 2021-05-10 KR KR1020227042887A patent/KR20230017793A/ko active Pending
- 2021-05-10 US US17/923,781 patent/US20230174648A1/en active Pending
- 2021-05-10 AU AU2021269130A patent/AU2021269130A1/en active Pending
- 2021-05-10 JP JP2022567837A patent/JP2023525298A/ja active Pending
-
2024
- 2024-02-28 US US18/590,865 patent/US12187797B2/en active Active
- 2024-11-27 US US18/963,213 patent/US20250197492A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7526099B2 (ja) | 抗ｃｄ３８抗体の皮下投薬 | |
| US20210163624A1 (en) | T cell receptor-like antibodies specific for a wti peptide presented by hla-a2 | |
| AU2018285731B2 (en) | Use of anti CD70 antibody ARGX-110 to treat acute myeloid leukaemia | |
| WO2020088605A1 (zh) | 针对cd19和cd3的同源二聚体型双特异性抗体及其制备方法和用途 | |
| GB2613464A (en) | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof | |
| Nair-Gupta et al. | A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia | |
| US20230270857A1 (en) | Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof | |
| JP2009502936A (ja) | Ｃｄ２０特異的結合分子の単一投与量 | |
| JP5834004B2 (ja) | ループス治療のための方法および組成物 | |
| JP7843824B2 (ja) | 抗体および使用方法 | |
| JP2024008945A (ja) | 膵島細胞の増殖を促進する方法 | |
| KR102486064B1 (ko) | 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자 | |
| JP2022525400A (ja) | フルオレセインエーテルリン脂質またはフルオレセインエーテルリン脂質前駆体と併用した抗フルオレセインｃａｒ ｔ細胞に対する拮抗薬としてのフルオレセインナトリウム | |
| JPWO2021226591A5 (https=) | ||
| JPWO2021226576A5 (https=) | ||
| WO2024041651A1 (en) | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies | |
| US20250051440A1 (en) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling | |
| AU2016349445A1 (en) | Blockade of RGMb for reducing transplantation-associated immune responses | |
| EP4349368A1 (en) | Therapy using combination of anti-cd26 antibody and immune checkpoint inhibitor | |
| KR20250116736A (ko) | Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법 | |
| HK40121520A (zh) | 抗-tnfr2抗体及其使用方法 | |
| EP4532546A1 (en) | Anti-tnfr2 antibodies and methods of use thereof | |
| JP2025084100A (ja) | 抗ｔｎｆｒ２抗体およびその使用の方法 | |
| CN119546640A (zh) | 用于治疗癌症的包含SIRPα融合蛋白和抗CD19抗体的组合疗法 | |
| CN120603847A (zh) | 抗il27r抗体及其使用方法 |